Plasma Metabolomic Effects of 8-Week Red Wine Consumption in CHD Patients

<u>P. Lekka¹</u>, M. Briscik², S. Déjean², A. Panara², E. Gikas³, N. Thomaidis², E. Fragopoulou⁴ and M. Dasenaki¹

¹ Food Chemistry Laboratory, Department of Chemistry, *National and Kapodistrian University of Athens*, Athens, 157 71, Greece

- ² Institut de Mathématiques de Toulouse, UMR5219, CNRS, UPS, Université de Toulouse, Cedex 9, 310 62 Toulouse, France
- ³ Analytical Chemistry Laboratory, Department of Chemistry, National and Kapodistrian University of Athens, Athens, 157 71, Greece
- ⁴ School of Health Science and Education, Department of Nutrition and Dietetics, *Harokopio University*, Athens, 176 76, Greece

INTRODUCTION



Moderate alcohol consumption, particularly **red wine**, has long been **associated with cardioprotective effects**, largely attributed to its polyphenolic content. However, the **long-term metabolic impact** of such consumption **in patients with coronary heart disease (CHD) remains poorly characterized**. To date, most studies have either focused on short-term interventions or observational associations without directly comparing ethanol versus polyphenol-rich alcoholic beverages. **This study** addresses this gap by conducting **the first 8-week randomized clinical trial using untargeted metabolomics.**

EXPERIMENTAL FLOW CHART



Data Processing

Non-targeted metabolomics data were acquired in AIF mode and processed in MS-DIAL. The dataset was log-transformed and Pareto-scaled in RStudio using MetaboAnalystR. Features with RSD > 30% were removed using QC samples. Multilevel analysis was performed with mixOmics and MetaboAnalystR to account for intra-subject variability.

HELLENIC REPUBLIC

National and Kapodistrian

de MATHEMATIQUES

XAPOKOΠΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ HAROKOPIO UNIVERSITY

University of Athens

RESULTS



Figure A1. Partial least squares discriminant analysis (PLS-DA) of the red wine trial, with adjustment for inter-individual variability (multilevel).



Figure A2. Multilevel sparse PLS-DA (sPLS-DA) of the red wine trial, with top 10 metabolites.



Figure B. Scaled heatmap of the top 20 discriminating metabolites identified by multilevel sPLS-DA (10 from each component), illustrating inter-individual and temporal variation across T0, T1, and T2.



CONCLUSIONS / FUTURE PERSPECTIVES

- 1. **Metabolic Changes:** Red wine consumption induces significant metabolic shifts, with key metabolites increasing at T2 and others dicrease after T1.
- 2. Inter-Individual Variability: Substantial variability across subjects highlights the need for multilevel modeling to account for baseline differences.
- 3. **Metabolic Stabilization:** Some metabolites return to baseline (T0) by T2, indicating metabolic adaptation to red wine consumption.

"Future work will focus on annotating metabolites and integrating them into pathway analyses to uncover underlying metabolic mechanisms."

Related Literature

[1] J. M. Guilford and J. M. Pezzuto, "Wine and Health: A Review," 2011

[2] M. Lombardo, A. Feraco, E. Camajani, M. Caprio, and A. Armani, "Health Effects of Red Wine Consumption: A Narrative Review of an Issue That Still Deserves Debate," **2023**

- [4] E. **Fragopoulou**, M. Choleva, S. Antonopoulou, and C. A. Demopoulos, "Wine and its metabolic effects. A comprehensive review of clinical trials," **2018**
- [5] P. Lekka, E. Fragopoulou, A. Terpou, and M. Dasenaki, "Exploring Human Metabolome after Wine Intake A Review," **2023**